Detalhe da pesquisa
1.
Tissue-Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition.
Adv Sci (Weinh)
; 10(26): e2302611, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37400371